Spine Biologics Global Market Report 2024

The spine biologics market size has grown strongly in recent years. It will grow from $2.24 billion in 2023 to $2.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historical period can be attributed to several factors, including advancements in biotechnology, an aging population, a high incidence of spinal disorders, increased preference for minimally invasive procedures, heightened awareness about spine health, improvements in diagnostic techniques, and enhanced healthcare infrastructure.

The spine biologics market size is expected to see strong growth in the next few years. It will grow to $2.91 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The projected growth in the forecast period is expected to be driven by technological innovations, increasing adoption of regenerative medicine, rising investment in research and development, growing prevalence of obesity and sedentary lifestyles, expanding healthcare access in emerging markets, favorable regulatory approvals, and increasing collaborations and partnerships within the industry. Significant trends anticipated for this period encompass the emergence of novel regenerative therapies, integration of artificial intelligence in treatment planning, expansion of personalized medicine approaches, adoption of 3D printing for customized implants, and the development of bioengineered scaffolds for enhanced tissue regeneration.

The increasing incidence of road accidents is poised to drive the growth of the spinal biologics market in the foreseeable future. Road accidents, defined as unintended events involving one or more vehicles on public roads resulting in severe spinal injuries, necessitate advanced medical interventions for effective treatment and recovery. Globally, road accidents are on the rise due to various factors, including distracted driving, higher traffic volumes, inadequate road infrastructure, and impairment from alcohol and drugs. Spinal biologics play a crucial role in enhancing patient outcomes by promoting spinal fusion, accelerating healing, reducing surgical risks, improving pain management, and minimizing the need for revision operations. For example, data from the National Highway Traffic Safety Administration reveals that in the US alone, an estimated 42,915 individuals lost their lives in motor vehicle traffic crashes last year, representing a 10.5% increase from the 38,824 fatalities recorded in 2020. Hence, the escalating number of road accidents is fueling the expansion of the spinal biologics market.

Leading companies in the spinal biologics market are focusing on developing advanced products, such as synthetic bioactive bone grafts, to better cater to patient needs and maintain a competitive edge in the market. Synthetic bioactive bone grafts are artificial spine biologics engineered to support and enhance bone growth and healing in spinal fusion surgeries. For instance, Orthofix Medical Inc., a US-based spine and orthopedics company, introduced Opus BA in February 2022. Opus BA, available in putty and strip forms, serves as a scaffold for bone growth, which is reabsorbed and replaced by natural bone. It can be hydrated with autogenous bone marrow or autografted with saline and features an osteoconductive matrix comprising carbonate apatite bone mineral, bioactive glass, and Type 1 collagen, facilitating bone growth and resorption.

In August 2023, Xtant Medical, a US-based medical technology company, acquired specific assets and liabilities of domestic and international biologics and spinal fixation products from Surgalign Holdings Inc. for an undisclosed sum. This strategic acquisition is poised to bolster Xtant Medical's product portfolio and market presence in the orthopedic and spine surgery sectors, leveraging the combined capabilities of both entities. Surgalign Holdings Inc. is a US-based medical technology company specializing in spine biologics and spinal fixation products.

Major companies operating in the spine biologics market are Johnson & Johnson Services Inc., Medtronic PLC, Stryker Corporation, Baxter International Inc., B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Arthrex Inc., Integra LifeSciences Corporation, Bone Biologics Corp., InVivo Therapeutics Corp., RTI Surgical Inc., Paragon 28 Inc., LifeNet Health Inc., Xtant Medical Holdings Inc., Kuros Biosciences A.G., CoreLink LLC, Spinal Elements Inc., Life Spine Inc., Innovasis Inc., Camber Spine Technologies LLC, SurGenTec LLC, ChoiceSpine LLC, Cerapedics Inc, Aziyo Biologics, Amedica Corporation.

North America was the largest region in the spine biologics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spine biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the spine biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Spine biologics, also referred to as spinal biologics, encompass biologically derived materials employed in the treatment of spinal conditions and injuries. These materials are utilized to stimulate bone formation, accelerate healing, and enhance the outcomes of spine surgery, particularly spinal fusion procedures. They encompass a variety of products, including bone grafts, growth factors, cell-based therapies, and biological scaffolds.

The primary products within spine biologics include bone allografts, bone graft substitutes, platelet-rich plasma, and bone marrow aspirate therapy. Bone allografts are grafts sourced from donors rather than from the patient's own body. Spine biologics find application across various types of surgeries, including anterior cervical discectomy and fusion (ACDF), posterior lumbar interbody fusion (PLIF), transforaminal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), lateral lumbar interbody fusion (LLIF), and others. These products are utilized for diverse applications such as spinal fusion, treatment of spinal non-union and fractures, management of degenerative disc disease, among others. They are employed by various end users including hospitals, spinal surgery centers, orthopedic clinics, and others.

The spine biologics market research report is one of a series of new reports that provides spine biologics market statistics, including spine biologics industry global market size, regional shares, competitors with a spine biologics market share, detailed spine biologics market segments, market trends and opportunities, and any further data you may need to thrive in the spine biologics industry. This spine biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The spine biologics market consists of sales of bone morphogenetic proteins, synthetic bone grafts, and spine fusion systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.